Predict your next investment

Calvert Research company logo
HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

About Calvert Research

Calvert Research is a strategic advisory and equity investment firm with experience in preclinical drug development. Its knowledge base covers all aspects related to advancing early stage drug candidates toward human clinical testing such as drug manufacturing, drug product formulation, analytical/bioanalytical methods development and animal safety, toxicology, pharmacology, immunology, and pharmacokinetic testing. It offers a range of preclinical services through its CRO affiliate, Calvert Laboratories, in addition to subcontractors to design and execute customized drug development partnership programs with preclinical stage biopharmaceutical companies.

Calvert Research Headquarter Location

1225 Crescent Green Suite 115

Cary, North Carolina, 27518,

United States


Latest Calvert Research News

Recovery and central banks may support risk markets

Aug 3, 2021

The ongoing global recovery and accommodative policies of major central banks should support risk markets in the near term, according to Calvert Research and Management. However, investors should be aware that markets could become increasingly volatile depending on the course of monetary policy taken. “A focus on generating portfolio returns through credit risk versus duration risk is appropriate for the current environment — an environment characterized by strong economic and corporate fundamentals, talk of tapering at the Fed and a "go big" spending mentality in Washington,” Related News:  Vishal Khanduja, director of investment grade fixed- income portfolio management and trading, and Brian S. Ellis, fixed income portfolio manager, at Calvert, said in a note. “We expect this approach, combined with the flexibility to adjust positioning within and across sectors, can benefit fixed-income portfolios in the months ahead.” They said that due to the economic recovery and the inflation and yield implications of the significant deficit spending, investors should position for yield-curve steepening with an underweight to duration. “While we previously favoured higher-quality corporate bonds, lower-quality segments of the credit markets now offer attractive opportunities in our view,” they said. “There may still be room for spread compression here, particularly in select BBB- and crossover credits that are benefiting from the sustained reopening. “In the high-yield market, we see value in some rising star candidates that could be upgraded to investment grade, as well as select BB- and B-rated credits that are attractive in a low-default environment. “Within non-investment grade, our emphasis has remained on bank loans over bonds, in part due to their lower sensitivity to interest rates,” they concluded.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.